GNBT News and Press, Generex Biotechnology From 06/26/20

NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the treatment and prevention of cancer and infectious diseases NGIO is now a stand-alone public company with plans to list shares on Nasdaq MIRAMAR, Fla., June 26, 2020...

Generex Biotechnology ( OTCQB:GNBT -3.2% ) has filed a preliminary prospectus for an offering of 1M shares of Series A cumulative redeemable perpetual preferred stock at $33 per share and warrants to purchase up to 100K common shares at $15 per share. More news on: Generex Biotechnolog...

Generex Biotechnology ( OTCQB:GNBT ) announces , what it says, is a key milestone in the development of a COVID-19 vaccine, namely, the manufacture of 33 Ii-Key-SARS-CoV-2 peptides using antigenic epitopes (the parts of an antigen that elicit an immune response) predicted by computational a...

NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the treatment and prevention of cancer and infectious diseases NGIO advancing Ii-Key peptide vaccines against the SARS-CoV-19 pandemic Ii-Key Peptides Advancing to Clinic...

The entire world anxiously awaits good news in the race to develop a vaccine for novel coronavirus disease COVID-19 . And there are plenty of drugmakers hoping to be the bearers of some good news, including both big pharmaceutical companies and small biotechs. Some investors could be temp...

Submitted proposal to BARDA for start-to-finish funding to develop an approved, commercial Ii-Key peptide vaccine against the SARS-CoV-2 coronavirus SARS-CoV-2 epitope identification and selection completed Initiated GLP manufacturing of synthetic Ii-Key-SARS-CoV-2 peptides for screenin...

Prospective, randomized, single‑blinded, multi‑center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence Conclusion: AE37 Ii-Key peptide vaccine is safe and associated with DFS in sub-sets of breast cancer survivors...

Generex strategy offers ethical and safe solution to rapid vaccine development with Ii-Key-SARS-CoV-2 peptide vaccine SARS-CoV-2 mechanism of infection still largely unknown COVID-19 disease progression remains largely undefined Risk factors for hospitalization include age, cardiovascu...

Developing a vaccine against Covid19 is of obvious global importance. Vaccines stimulate immune systems to produce antibodies, similar to the subject being exposed to the disease. Production of antibodies and stimulation of immune systems help the human body to develop immunity against disease. ...

MIRAMAR, Fla., April 14, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) today announced that the company is working with corporate collaborators, academic advisors, and contract manufacturers, wi...